Treatment of MDR-TB: Is hepatotoxicity a problem?

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 5, 2012, Pages 571-

  Loddenkemper, Robert ^a   Schaberg, Tom ^a  

^a German Central Committee Against Tuberculosis DZK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ETHIONAMIDE; ISONIAZID; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ALCOHOL CONSUMPTION; BODY MASS; COMORBIDITY; DRUG WITHDRAWAL; EDITORIAL; HOMELESSNESS; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER TOXICITY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRISONER; PROGNOSIS; RESPIRATORY FAILURE; SEIZURE; SMOKING; VIRUS HEPATITIS;

ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MALE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84859723742     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0199     Document Type: Editorial

References (5)

1. Saukkonen J J, Cohn D L, Jasmer R M, et al. An offi cial ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952. (Pubitemid 44564795)
2. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
3. Keshavjee S, Gelmanova I Y, Shin S S, et al. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int J Tuberc Lung Dis 2012; 16: 596-603.
4. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
5. Johnston J C, Shahidi N C, Sadatsafavi M, FitzGerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.